Product/Composition:- | Crizanlizumab |
---|---|
Strength:- | 100 mg/10 mL (10 mg/mL) |
Form:- | IV Infusion |
Reference Brands:- | Adakveo®(EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Crizanlizumab (Adakveo®) is an FDA- and EMA-approved IV biologic for sickle cell disease, available for B2B pharma distribution in the US and EU to reduce pain crises in affected patients.
rizanlizumab (Adakveo®) is a breakthrough biologic therapy for sickle cell disease, available for B2B pharmaceutical distribution across the US and EU markets. It is a humanized monoclonal antibody (anti-P-selectin) used to reduce the frequency of painful vaso-occlusive crises in patients with sickle cell anemia. Approved by the FDA and EMA, Crizanlizumab is supplied as a 100 mg/10 mL IV infusion, ideal for hospital and specialty clinic use. Pharma B2B partners benefit from secure supply chains, regulatory-compliant sourcing, and access to one of the most innovative therapies in hematology. Reliable distribution and market-ready packaging ensure smooth commercialization across regulated markets.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications